Next Article in Journal
Plant Polyphenols and Their Potential Benefits on Cardiovascular Health: A Review
Next Article in Special Issue
Enantiomeric Complexes Based on Ruthenium(III) and 2,2′-Biimidazole: X-ray Structure and Magnetic Properties
Previous Article in Journal
A Simple Schiff Base Probe for Quintuplicate-Metal Analytes with Four Emission-Wavelength Responses
Previous Article in Special Issue
H(N3)dap (Hdap = 2,6-Diaminopurine) Recognition by Cu2(EGTA): Structure, Physical Properties, and Density Functional Theory Calculations of [Cu4(μ-EGTA)2(μ-H(N3)dap)2(H2O)2]·7H2O
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Oxidation of the Platinum(II) Anticancer Agent [Pt{(p-BrC6F4)NCH2CH2NEt2}Cl(py)] to Platinum(IV) Complexes by Hydrogen Peroxide

1
School of Chemistry, Monash University, Clayton, VIC 3800, Australia
2
College of Science, Technology & Engineering, James Cook University, Townsville, QLD 4811, Australia
*
Author to whom correspondence should be addressed.
Molecules 2023, 28(17), 6402; https://doi.org/10.3390/molecules28176402
Submission received: 1 August 2023 / Revised: 22 August 2023 / Accepted: 25 August 2023 / Published: 1 September 2023
(This article belongs to the Special Issue Synthesis and Applications of Transition Metal Complexes)

Abstract

:
PtIV coordination complexes are of interest as prodrugs of PtII anticancer agents, as they can avoid deactivation pathways owing to their inert nature. Here, we report the oxidation of the antitumor agent [PtII(p-BrC6F4)NCH2CH2NEt2}Cl(py)], 1 (py = pyridine) to dihydroxidoplatinum(IV) solvate complexes [PtIV{(p-BrC6F4)NCH2CH2NEt2}Cl(OH)2(py)].H2O, 2·H2O with hydrogen peroxide (H2O2) at room temperature. To optimize the yield, 1 was oxidized in the presence of added lithium chloride with H2O2 in a 1:2 ratio of Pt: H2O2, in CH2Cl2 producing complex 2·H2O in higher yields in both gold and red forms. Despite the color difference, red and yellow 2·H2O have the same structure as determined by single-crystal and X-ray powder diffraction, namely, an octahedral ligand array with a chelating organoamide, pyridine and chloride ligands in the equatorial plane, and axial hydroxido ligands. When tetrabutylammonium chloride was used as a chloride source, in CH2Cl2, another solvate, [PtIV{(p-BrC6F4)NCH2CH2NEt2}Cl(OH)2(py)].0.5CH2Cl2, 3·0.5CH2Cl2, was obtained. These PtIV compounds show reductive dehydration into PtII [Pt{(p-BrC6F4)NCH=CHNEt2}Cl(py)], 1H over time in the solid state, as determined by X-ray powder diffraction, and in solution, as determined by 1H and 19F NMR spectroscopy and mass spectrometry. 1H contains an oxidized coordinating ligand and was previously obtained by oxidation of 1 under more vigorous conditions. Experimental data suggest that oxidation of the ligand is favored in the presence of excess H2O2 and elevated temperatures. In contrast, a smaller amount (1Pt:2H2O2) of H2O2 at room temperature favors the oxidation of the metal and yields platinum(IV) complexes.

Graphical Abstract

1. Introduction

The serendipitous discovery of cisplatin as an anticancer drug has served humankind for decades [1,2]. Despite its success in treating testicular, ovarian, head and neck, small-cell lung, and bladder cancers, with a 90% cure rate for testicular cancer [3,4,5,6,7,8], cisplatin still has limited applications owing to natural and acquired resistance against tumors [9,10]. Additionally, it causes severe side effects, such as nephrotoxicity, neurotoxicity, and myelosuppression [9,10,11,12,13,14,15,16], and it can only be administered intravenously. The need to address these limitations and increase their applications to a broader spectrum of cancers produced cisplatin derivatives and new PtII compounds. However, only PtIV compounds showed the potency to shift the paradigm because their relatively inert nature reduces the extent of side reactions—it makes them less toxic and provides the possibility of their oral administration [8,17,18,19,20] for improved quality of life of cancer patients. Furthermore, they are more water-soluble than PtII drugs and are more easily absorbed in the gastrointestinal tract; their high lipophilicity causes enhanced diffusion through the cell membrane, and they are not cross-resistant with cisplatin [21,22,23].
Generally, PtIV compounds (e.g., tetraplatin, iproplatin, and satraplatin) are considered to be PtII prodrugs [24,25]. They are relatively inert to ligand substitution reactions due to their electronic configuration, but liable to two-electron reduction. They are reduced to their active PtII analogue in vivo by biomolecules, such as glutathione (GSH), by the loss of their axial ligands [8,26,27]. The ease with which PtIV complexes are reduced to PtII depends on the nature of the axial ligands [28], which affect the reduction potential (Ered) for the PtIV/II process. For example, the order of the ease of reduction of PtIV [28] in tetraplatin (axial ligand Cl) [29], JM216 (axial ligand CH3COO) [30], and Iproplatin (axial ligand OH) [31] is Cl > RCO2 > OH. Photoactive PtIV complexes have also been explored for better efficiency [32,33]. Nanoparticle-based drug delivery of PtIV complexes has been introduced to address the resistance issues and further lower the toxicity [34,35]. In most cases, the reduction of the PtIV prodrug generates the parent PtII compound by the loss of two axial ligands [27,36]. Some reports also mentioned the formation of more than one reduction product, depending on the reducing agents used [37,38].
The need to find better drugs led to “rule breaker” [39] or “non-traditional” drugs [40], which violate structure–activity rules [41]. One such example is the polynuclear platinum compound BBR3464 [42,43,44]. Other “rule breakers” include two classes of organoamidoplatinum(II) compounds, namely, Class 1, [Pt{N(R)CH2}2(py)2] (R = polyfluoroaryl), with no H atoms on the N-donor atoms, and Class 2, trans-[Pt{N(R) CH2CH2NRʹ2}X (py)] (R = polyfluoroaryl; R′ = Et, Me; and X = Cl, Br, I), with trans amine ligands and trans anionic ligands, and no H atoms on the N-donor atoms (see Figure 1). Both classes show promising anticancer activity in vitro and in vivo [45,46,47]. The investigation of DNA binding properties by Resonant X-ray emission spectroscopy (RXES) shows that after hydrolysis of [Pt{N(p-HC6F4)CH2}2(py)2] (Pt-103) (py = pyridine), the [N(p-HC6F4)CH2]22− moiety behaves as a leaving group, and hydroxylation of the Pt center generates a hydrolyzed species, which then reacts with DNA and preferentially coordinates to the adenine site, rather than the guanine site [48]. This could explain why Pt-103 is biologically active against cisplatin-resistant cell lines.
PtIV compounds are generally six coordinate octahedral complexes and can be synthesized by oxidative addition of four coordinate square planar PtII compounds. However, some five coordinat PtIV complexes also have been reported to be formed in the oxidation of PtII to PtIV [49]. The Platinum Group Metals (PGMs) in higher oxidation states (as PtIV) have been reported as possible intermediates in some organic synthetic procedures due to their lower stability [50,51,52,53].
Oxidation of platinum(II) complexes with H2O2 has been reported to produce trans dihydroxidoplatinum(IV) complexes [54,55,56,57,58,59,60]. Some Class I (organoamido)platinum(IV) compounds have shown high anticancer activity in vivo against the ADJ/PC6 tumor line [54]. Some PtIV complexes with large negative Ered values, such as [Pt{((p-HC6F4)NCH2)2(py)2}(Cl)2], [Pt{((p-HC6F4)NCH2)2(py)2}(OH)2] (Pt103(OH)2), and [Pt{((p-HC6F4)NCH2)2(py)2}(Cl)(OH)], are effective against cisplatin-resistant cell lines [54]. The last two are even more active than the PtII precursor Pt-103. This suggests that either the PtIV complexes themselves are active, or they are reduced in vivo near the target and prevent premature reduction [54]. The electrochemical oxidation of Class 2 complexes produced mononuclear, formally PtIII, species [61,62]. The formation of PtIV species was not observed in these electrochemical studies. Recently, we reported the oxidation of the Class 2 complex [Pt(p-BrC6F4)NCH2CH2NEt2}Cl(py)], (1) by an excess of H2O2 under forcing conditions, which involved heating in different solvents [47]. Under these conditions, two types of ligand oxidized organoenamineamidoplatinum(II) complexes, namely, unsubstituted [Pt(p-BrC6F4)NCH=CHNEt2}Cl(py)], 1H and ethene-substituted [Pt(p-BrC6F4)NCH=C(X)NEt2}Cl(py)], 1X (X = Cl, Br), along with [Pt(p-BrC6F4)NCH=C(H0.25Br0.75)NEt2}Cl(py)], 1H0.251Br0.75, were obtained. (Scheme 1 top) [47]. However, the formation of PtIV complexes was not observed.
Here, we report the formation of PtIV dihydoxidoplatinum(IV) complexes, which are isolated from the oxidation of 1 with H2O2 under milder conditions without heating. Changes in stoichiometry, temperature, solvents, and the addition of chloride were used to achieve higher selectivity of the products. These PtIV compounds undergo reductive dehydration, that is, reduction of PtIV to PtII over time in the solid state, as determined by X-ray powder diffraction characterization, forming organoenamineamideplatinum(II) complexes with an oxidized coordinating ligand.

2. Results and Discussion

In the present work, the chemical oxidation of 1 was undertaken with H2O2 at room temperature in a range of solvents to determine if isolable PtIV complexes could be obtained under mild conditions. The H2O2 oxidation in acetone produced the gold-colored dihydroxidoplatinum(IV) compound 2·H2O(gold) as a hydrate, along with 1H, and 1H0.251Br0.75 organoenamineamidoplatinum(II) compounds as minor products (Scheme 1(bottom, red)).
The PtIV complex 2·H2O(gold) showed slow reductive dehydration in the solid state to produce the organoenamineamide PtII complex 1H, which is the product of oxidation of the ligand [47] (see below). Earlier studies showed that some PtIV complexes also exhibit reductive elimination similar to what is better known for PdIV complexes [50].
The selectivity for formation of PtIV compounds was enhanced by optimizing the experimental conditions to produce the outcome shown in Scheme 2. We proposed previously that, in the absence of any other source of Cl in the reaction mixture, the chloride needed to form 1Cl is generated from the oxidation of the Pt-Cl bond of 1 [47]. Thus, H2O2 oxidation reactions of 1 were also performed with deliberately added chloride to examine whether this would enhance the yield of 1Cl or would promote the formation of PtIV complexes, as the Pt-Cl bond should remain intact due to the presence of excess chloride. Scheme 2 is a schematic representation of the major products obtained from the oxidation of 1 with limited H2O2 under a range of experimental conditions. Two differently colored samples of 2·H2O, red and gold (2·H2O(red) and 2·H2O(gold)), were isolated. The amounts of the reagents and the yields of the products are shown in Table 1. The results demonstrate that the addition of chloride enhances the formation of dihydroxidoplatinum(IV) complexes.
The H2O2 oxidation reaction of 1 in the presence of LiCl in CH2Cl2 at room temperature produced the PtIV complex 2·H2O in two colors, red and golden crystals (see experimental section). Both were characterized by X-ray crystallography (see below) and microanalyses. Both have one molecule of water of crystallization per molecule of the complex (some previous works have also reported the observation of transient red color upon oxidation of cisplatin with chlorine [63,64]). Related results were obtained with added tetrabutylammonium chloride, in CH2Cl2 (see Table 1 and Experimental section). In this case, a deep-red-colored PtIV complex containing 0.5 of a CH2Cl2 molecule in the asymmetric unit, 3·0.5CH2Cl2, with some 2·H2O(gold) was obtained. A few crystals of NBu4[PtCl3(py)] also were obtained and characterized by X-ray crystallography only. All the experimental results suggest that adding chloride simplifies the reaction by preventing the dissociation oxidation of the Pt-Cl bond.
The mechanism for H2O2 oxidation of PtII to PtIV has been reported as single-step two-electron oxidation or as two very rapid one-electron processes that exclusively produce trans-hydroxide complexes [65]. In this oxidation reaction, the square planar configuration of the original PtII complex is retained, and the two hydroxido ligands coordinate trans to each other. A 195Pt NMR study has suggested that one of the trans-coordinated hydroxido ligands originates from H2O2 and the other from the solvent water [66,67].
Notably, all PtIV solvate complexes show reductive dehydration, i.e., from PtIV to PtII species. However, the resulting PtII species is not the parent compound 1, as is generally the case with PtIV species. Instead, an organoenamineamidoplatinum(II) compound 1H with an oxidized coordinating ligand is formed (below).

2.1. X-ray Crystal Structures

The molecular structures of 2·H2O(red) and 2·H2O(gold) PtIV complexes are shown in Figure 2, and that of 3 in Figure 3. 2·H2O(gold) crystallizes in the space group (C2/c), whereas 2·H2O(red) crystallizes in the Cc space group. Despite these space group differences, their unit cells are virtually identical (Table 2), as are their X-ray powder diffractograms generated from their single-crystal data (Figure S1). Accordingly, the structures are the same, despite the optimum solutions being in different space groups. The molecular structure of 2·H2O(red) has the same ratio of complex to solvent of crystallization (water) as in 2·H2O(gold). In 2·H2O(red), two dihydroxidoplatinum(IV) molecules bridged with two water molecules by H-bonding are present in the asymmetric unit (Figure 2c), whereas in 2·H2O(gold), a single molecule of 2 is associated with a single water molecule of crystallization (Figure 2a). However, the crystal structure of 2·H2O(gold) extended to two asymmetric units (Figure 2b) reveals the same structure as in the asymmetric unit of 2·H2O(red). Red and yellow compounds with essentially the same structure are observed in the case of yellow and red mercuric oxide, ref [68] where the difference is attributed to particle size. Likewise, [RuBr2(CO)2(tpy)] (tpy = 2,2′:6′,2′′-terpyridine) exists in red and yellow forms with essentially the same structure [69]. Although the powder diffractograms of bulk 2·H2O(red) and 2·H2O(gold) show significant differences (Figure S7), this is attributed to different rates of reductive dehydration in the solid state (see below). 3·0.5CH2Cl2 crystallizes in the C2/c space group with one formula unit in the asymmetric unit (Figure 3a), and the crystal packing shows a hydrogen-bonded dimer (Figure 3b).
All PtIV solvate complexes have an octahedral stereochemistry around the Pt metal atom with trans hydroxido axial ligands. The bond lengths are listed in Table 3, the bond angles are in Tables S1 and S2, and the crystal data are in Table 2. The OPtO angles in 2·H2O(gold), 2·H2O(red), and 3·0.5CH2Cl2 are 177.7(3), 177.9 (3)/ 177.8(4) (molecules A and B), and 176.57(13), respectively. These angles are comparable to 179.73(9) in [Pt{((p-HC6F4)NCH2)2}(py)2(OH)2] ([Pt103(OH2)]) [54], as expected for a linear and trans arrangement of axial ligands. Equatorial positions have a square planar arrangement of the donor atoms, as in the parent compound 1. The Pt-O bond lengths shown in Table 3 are similar to those for the dihydroxidoplatinum(IV) complex, [Pt103(OH2)] [54], shown in Table 3. The Pt-N bond lengths are expected to lengthen with an increase in the coordination number from 4 to 6. However, an increase in the oxidation state from +2 to +4 is expected to shorten the Pt-N bond lengths. Apparently, these contrary effects cancel each other out, so the Pt-N bond lengths remain close to those of the parent platinum(II) compound (1) at the three-esd level. The angles between OH and other donor atoms in the square planar arrangement are close to 90°, consistent with octahedral stereochemistry.
The bond angles around the amide N in 2·H2O(red)) (108.8 (7) + 117.4 (8) + 118.2 (7) = 344.4°) and in 3 (108.054 (18) + 117.856 (17) + 116.878 (6) = 344.8°) show distortion from tetrahedral (∑328.5°) towards triangular (∑360°). However, the N atoms have less trigonal character than in the platinum(II) complexes 1 (∑356.9°) and 1H (∑357°).
These PtIV complexes show a range of inter- and intramolecular H-bonding (Figure 2 and Figure 3), as also observed for related PtII compounds [70]. The interaction distances are listed in Table 4. In 2·H2O(red) and 2·H2O(gold), both H atoms of the trans-OH groups are facing toward the o-F atoms of the polyfluoroaryl ring. However, in 3, one of the H atoms of the trans-OH ligands, faces away, as it makes an H-bond with Br(p-BrC6F4) of an adjacent molecule with an H⋯Br distance, 3.0993(5), as shown in Figure 3.
A few crystals of [NBu4][PtCl3(py)] were obtained as a minor product from the H2O2 oxidation reaction of 1 with added tetrabutylammonium chloride in CH2Cl2 (see Experimental). The compound [NBu4][PtCl3(py)] could only be characterized by X-ray crystallography due to the poor yield. The molecular structure of [NBu4][PtCl3(py)] is shown in Figure S2. In the asymmetric unit, only half of the molecule is present, and the other half is symmetrically generated. Crystallographic data are given in Table S3, and selected bond lengths and angles are listed in Table S4.
Satisfactory microanalyses were obtained for all three 2·H2O(red), 2·H2O(gold), and 3·0.5CH2Cl2 PtIV complexes. All were consistent with the presence of H2O in 2 and 0.5 CH2Cl2 in 3 crystal lattices (see Experimental section). The characteristic ν(OH) bands of dihydroxidoplatinum(IV) complexes were observed in IR spectra between (3500 and 3700 cm−1) in the expected range (ν(OH) 3760–3500 cm−1) for metal hydroxides [54,71]. Strong ν(C-F) absorption bands appear at a comparatively higher wavenumber, i.e., at 968 cm−1 in 2(red) and 3 as compared to the PtII precursor 1 (956 cm−1), as also observed for Pt103 (926 cm−1) and Pt103(OH)2 (938 cm−1) [54]. The spectra show C-H out-of-plane deformation bands of py at 763 cm−1.

2.2. Powder X-ray Diffraction (PXRD) Study

Powder diffraction patterns for bulk 2·H2O(red) and 2·H2O(gold) exhibit differences (Figure S7) and also differ from the identical patterns generated from single-crystal data (Figure S1). These solids, especially red 2·H2O, changed in physical appearance with time (over almost 90 days) and turned from deep-red crystals (block) into a mixture of red powder and some yellow solid.
A comparison of the PXRD pattern for a bulk sample of 2·H2O(red) with those calculated from the single-crystal data for the platinum(II) complex [Pt(p-BrC6F4)NCH=CHNEt2}Cl(py)], 1H [47] (Scheme 1) and single crystals of 2·H2O(red) (see Figure S8) clearly shows that PtIV 2·H2O(red) and 1H both are present in the bulk sample of stored 2·H2O(red). A comparison between the PXRD patterns of the bulk sample of 2·H2O(gold) with those calculated from the single-crystal data for 1H and single crystals of 2·H2O(gold), (Figure S9), clearly shows 2·H2O(gold) and 1H both are present in the bulk sample of 2·H2O(gold). However, 1H is present in larger amounts in this bulk sample than in the bulk sample of 2·H2O(red).
All observations and the experimental facts confirm that these PtIV samples undergo reductive dehydration to produce a PtII complex with an oxidized ligand, where the rate is faster for 2·H2O(gold) than for 2·H2O(red).
A yellow crystal of 1H was collected from the bulk sample of 2·H2O(red), and X-ray diffraction data were obtained (see Table S5). The crystal structure showed twinning, but the cell parameters were consistent with 1H [47]. Another yellow crystal of co-crystallized ([Pt(p-BrC6F4)NCH=CHNEt2}Cl(py)], 1H and [Pt(p-BrC6F4)NCH=C(Cl)NEt2}Cl(py)], 1Cl, 1H/Cl) also was collected from a bulk sample of 2·H2O(gold), and X-ray diffraction data were obtained (see Table S5). The crystal structure showed twinning, but the cell parameters were consistent with co-crystallized (1H/Cl) [47]. The mechanism for formation of 1Cl by reductive dehydration in the solid state is not fully understood, but it is probably via a similar path to that proposed for its formation in the oxidation of 1 by H2O2 under aggressive conditions [47].

2.3. Isolation of PtIV from the Solution of an Aged Bulk Sample

To examine if platinum(IV) species can be recovered from solution, an aged sample of 3·0.5CH2Cl2 was returned to the reaction mixture from which 3·0.5CH2Cl2 was isolated in the first place and was completely dissolved in CH2Cl2 to obtain an homogeneous solution. Crystallization from the CH2Cl2/hexane mixture enabled the isolation of red crystals of [PtIV{(p-BrC6F4)NCH2CH2NEt2}Cl(OH)2(py)].H2O, 2·H2O(red) having the same cell parameters (see Table S6) as in Table 2. However, 3 (with 0.5 CH2Cl2 in the crystal lattice) could not be isolated. A yellow crystal of co-crystallized (1H/Cl) again was isolated from the solution, and the unit cell parameters collected (Table S6) are in agreement with those reported in Table S5. Some pale-yellow crystals were also isolated from the solution, and X-ray diffraction data were obtained, establishing the identification as [NBu4][PtCl3(py)] (Figure S2), as also isolated from the preparation of 3·0.5CH2Cl2 (above).

2.4. NMR Spectroscopy

The rearrangement of the PtIV complexes into the PtII species, 1H, was initially detected by NMR spectroscopy. Notably, no PtIV species was detected in the NMR spectra of 2·H2O(gold), and only 1H was observed (see Experimental section), showing that the rate of reductive dehydration for 2·H2O(gold) is fast in solution. In the 19F NMR spectrum of 2·H2O(red) in deuterated acetone, four resonances in a 1:1:1:1 ratio are present at −138.24, −138.34, −140.64, and −148.16 ppm, together with very low-intensity resonances of precursor compound 1. The highest and lowest frequency resonances correspond to those of 1H [47]. The other two resonances show the small separation observed for F2,6 and F3,5 of the p-HC6F4 group in other 2,3,5,6-tetrafluorophenylethane-1,2-diaminatoplainum(IV) complexes [54]. The signals are shifted to a higher frequency than for the corresponding resonances of the PtII precursor due to the higher oxidation state.
In the 1H NMR spectrum of 2·H2O(red) in (CD3)2CO, two separate resonance sets were observed for ortho, meta, and even for the para protons of the pyridine ligands. That is only possible when two species are present in the solution. One set of resonances corresponds to those reported for 1H [47]. The remaining resonances are attributed to those of the platinum(IV) complex 2 in a 1:1 ratio with 1H. Further to this assignment, in the 1H NMR spectra, one of the two sets of pyridine 1H resonances appears at a higher frequency than the other set. This set of resonances is assigned to pyridine of a platinum(IV) species. 1H and 19F NMR spectra of 2·H2O(red) in CD2Cl2 also showed both species, confirming that this observation is not solvent-specific.
Similar behavior was shown by 3·0.5CH2Cl2. In the solution, 3·0.5CH2Cl2 produces a PtIV species and 1H, as observed for 2·H2O(red). However, this compound also shows the chloro-substituted organoenamineamide species [Pt(p-BrC6F4)NCH=C(Cl)NEt2}Cl(py)], 1Cl [47] in solution. In the 19F NMR spectrum, the resonances at −137.96 and −148.61 ppm (almost 10 ppm apart) are due to F 3, 5 (2F) and F 2, 6 (2F) of 1H. Those at −137.63 and −142.25 ppm (almost 4 ppm apart) represent 2F (F 3, 5) and 2F (F 2, 6) of the PtIV species, 3, and at −137.27 and −148.46 ppm (almost 10 ppm apart), they are 2F (F 3, 5) and 2F (F 2, 6) of 1Cl. Some extracted data from complex NMR spectra of these compounds are shown in Table 5. For 2·H2O(gold), only 1H was observed, and the PtIV complex was not observed; therefore, only the data for 1H are shown in Table 5. The complete NMR data and integrations showing relative amounts are provided in the Experimental section.
All the above observations indicate that PtIV complexes show reductive dehydration to PtII species, mainly 1H, in solution (Equation (1)) and in the solid state. In this rearrangement, the metal is reduced, and the ligand is oxidized with water loss. This is a net dehydration reaction, as given in Equation (1). The rate at which Equation (1) occurs is strongly dependent on the environment. After the peroxide reaction, these PtIV complexes were isolated with the addition of water (see Experimental section), so Equation (1) is not favored. In the solid state, slow loss of water or dehydration occurs. In an organic solvent with minimal water content, water loss is facilitated and faster than in the solid state.
P t I V p - B r C 6 F 4 N C H 2 C H 2 N E t 2 C l O H ) 2 p y P t I I p - B r C 6 F 4 N C H = C H N E t 2 C l p y + 2 H 2 O

Variable-Temperature NMR Spectra

To monitor Equation (1) in solution further, the temperature dependence of 1H and 19F NMR resonances was examined. The spectra were taken at 20° intervals, from 25 °C to −60 °C, and are shown in Figures S3–S6. The temperature variation study was performed almost 60 days after the NMR spectra were first recorded for 2·H2O(red) (Experimental section), when PtII and PtIV were present in an almost 1:1 ratio. The integration ratios of PtIV to PtII are 40% and 60%, respectively, at 25 °C.
1H and 19F NMR spectra do not show a any significant change in the temperature range of 25 °C to −60 °C. The F 2, 6 and F 3, 5 resonances for PtII do not show any change with variation in the temperature. However, a slightly increased separation between F 3, 5 resonances of PtII and PtIV was observed in the 19F NMR spectra, with some broadening and reduced definition of F 3, 5 of the PtIV species. The broadening is attributed to crystallization at lower temperatures. The integration ratio of PtIV to PtII decreases upon cooling, consistent with partial crystallization of the former.
When the solution was heated from 25 °C to 50 °C and the spectra were collected, the 1H resonances showed an increase in intensity in the 19F NMR spectra consistent with the further extent of the reaction in Equation (1), as shown in Figure S6.

2.5. Electrospray MS Measurements

As described in the supporting information, no PtIV complexes were detected via electrospray MS measurements. Similar to what was observed for trans-organoenamineamidoplatinum(II) complexes [47], the starting material 1 was observed.

3. Materials and Methods

3.1. Chemicals

The solvents acetone, dichloromethane, acetonitrile, ethyl acetate, and n-hexane were HPLC grade. Hydrogen peroxide (30% solution in water) (Merck) was stored at −4°C. MnO2, NBu4Cl, and LiCl were from Sigma Aldrich and used as received. The Class 2 organoamidoplatinum(II) complex, trans-[Pt{(p-BrC6F4)NCH2CH2NEt2}Cl(py)] (1), was synthesized by using the literature method [62].

3.2. Instrumentation/Analytical Procedure

NMR spectra were recorded in deuterated solvents with Bruker DPX 300, 400, or 600 spectrometers (Billerica, MA, USA) supported by Top Spin NMR 4.3.0 software on a Windows NT workstation. CFCl3 and tetramethylsilane were used for the internal calibration of 19F NMR and 1H NMR spectra, respectively. Infrared spectra were recorded on a Perkin-Elmer 1600 FT-IR spectrophotometer as Nujol and hexachlorobutadiene (HCB) mulls between NaCl plates or recorded with an Agilent Cary 630 (Agilent Technologies Ltd., Yarnton, UK) attenuated total reflectance (ATR) spectrometer in the range 4000–600 cm−1. Low-resolution ESI measurements were recorded on a Waters micromass ZQ QMS connected to an Agilent 1200 series HPLC system. High-resolution accurate mass measurements were performed on a TOF (Agilent) instrument with a multimode source by using the dual methods ESI (electrospray ionization) and APCI (atmospheric pressure chemical ionization). Microanalyses were carried out by the Science Centre, London Metropolitan University Elemental Analysis Service. An electrothermal IA6304 apparatus was used to measure the melting points (uncalibrated) of the compounds. PXRD patterns were measured using a Bruker D8-Focus diffractometer (Billerica, MA, USA) with a 1° divergence slit, 0.2° receiving slit, and carbon monochromators (Cu-Kα radiation, λ = 1.5406 Å) in the range 2θ = 2–60° at 0.02° increments, at room temperature. The Mercury 4.3.0 software was used to generate the calculated powder patterns generated from the single-crystal diffraction models.

3.3. X-ray Crystallography

X-ray diffraction data obtained from single crystals of 2·H2O(gold), [NBu4][PtCl3(py)], and 3 were collected at a wavelength of λ = 0.712 Å using the MX1 beamline at the Australian Synchrotron, Victoria, Australia, with Blue Ice [72], a GUI using the same method as mentioned in the Experimental section of the previous report [62]. Data were processed with the XDS [73] version 20230630 software package. The structures were solved using direct methods with SHELXS-97 [74] and refined using conventional alternating least-squares methods with SHELXL-97 [74]. Single crystals of 2·H2O(red) were loaded onto a fine glass fiber or cryoloop using hydrocarbon oil and the data collected at 123K using an open-flow N2 Oxford Cryptosystem. A Bruker Apex II diffractometer was used to collect the data, which was processed using the SAINT [75] program. The program OLEX2 [76] was used as the graphical interface. All non-hydrogen atoms in the structures were refined anisotropically, and hydrogen atoms attached to carbon were placed in calculated positions and allowed to ride on the atom to which they were attached. The positions of the hydrogen atoms attached to the oxygen atoms were experimentally located and refined by using multiple refinement cycles.
Crystallographic data for all the structures reported in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary number CCDC 2272032 for 2·H2O(gold), 2272033 for 2·H2O(red), 2272037 for 3, and 2280550 for [NBu4][PtCl3(py)]. Copies of the data can be obtained free of charge at www.ccdc.cam.ac.uk/data_request/cif (accessed on 31 July 2023).

3.4. Experimental Section

3.4.1. Oxidation of 1 with H2O2

In acetone: 1 (0.630 g, 1.0 mmol) was dissolved in 16 mL acetone, and (0.2 mL, 2.0 mmol) of 30% H2O2 solution was added. The reaction mixture was stirred at room temperature for 12 days. The color of the solution changed from initially yellow to deep red and then to reddish-orange; MnO2(see the warning below) [77] (2 g) was added at that time. After filtration and evaporation of the solution to 5–6 mL, distilled water (20 mL) was added, producing a cloudy solution with deep-red oil. The cloudy solution was decanted off, filtered, and a red–brown powder was collected. Crystallization of the red–brown powder from acetone/hexane produced crystals of 1H by slow evaporation, characterized by X-ray single-crystal diffraction, 1H and 19F NMR, and mass spectrometry.
(a) [Pt{(p-BrC6F4)NCH=CHNEt2}Cl(py)] (1H): Metallic gold-colored blocks. (0.002 g, 1.4% crystal yield). 19F NMR (CD3(CO)2): −148.2 [m, 2 F, F 2, 6], −138.2 [m, 2 F, F 3,5]. 1H NMR (CD3(CO)2): 1.56 [td, 6 H, 3JH,H 7 Hz, NCH2CH3,], 2.30 [m, 2 H, NCHAHBCH3,], 3.43 [m, 2 H, NCHBHACH3,], 3.75 [d, 3JH,H 3.45 Hz, 3JH,Pt 34 Hz, 1 H, CHNEt2], 6.07 [m with 195Pt satellites, 3JH,Pt 50 Hz, 1 H, CHN(p-BrC6F4)], 7.19 [m, 2 H, H 3, 5 (py)], 7.74 [tt, 3JH,H 7.8 Hz, 4JH,H 1 Hz, 1 H, H 4 (py)], 8.42 [d with 195Pt satellites, 3JH,H 5.6 Hz, 3JH,Pt 30 Hz, 2 H, H 2, 6 (py)]. All these data (IR and ESI m/z (+ve) are given in SI) agree withthose reported for 1H [47].
The remaining red–orange filtrate was concentrated using a rotatory evaporator. The entire solution changed color from reddish-orange to gold, and more red–brown oil was obtained. After separation from the oil, the gold-colored filtrate produced shiny golden flakes upon cooling at −10 °C. These golden flakes were recrystallized from acetone/water, and gold-colored crystals of the platinum(IV) complex 2·H2O(H2O) were obtained. After collecting crystals, slow evaporation of the remaining mother liquor produced [Pt{(p-BrC6F4)NCH=C(H0.25Br0.75)NEt2}Cl(py)], 1H0.25Br0.75, as characterized by X-ray crystallography, yielding the same unit cell as reported earlier [47]. The red–brown oil was dissolved in acetone, and many unsuccessful attempts of crystallization were made with various solvents. 1H and 19F NMR revealed the presence of PtIV species, 2·H2O(H2O), with some Pt(py)2Cl2. Some colorless shiny crystals of trans-Pt(py)2Cl2 were obtained after a long period and were characterized by X-ray diffraction.
(b) cis, cis, trans- [Pt{(p-BrC6F4)NCH2CH2NEt2}Cl(py)(OH)2].H2O 2·H2O(gold): Metallic gold blocks. (0.160 g, 25% yield). M.P. = 192 °C (dec.). Elemental analysis calcd for C17H23Cl1F4N3Pt1Br1O3 (M = 702.02): C, 29.03%; H, 3.30%; N, 6.04%. Found: C, 29.20%; H, 3.17%; N, 6.08%.
*In solution, 2·H2O(gold) yielded 1H:
19F NMR, 1H NMR, and MS data agree with those of 1H above.

3.4.2. Oxidation of 1 with 30% H2O2 in the Presence of LiCl

1 (0.325 g, 0.5 mmol) was dissolved in 15 mL CH2Cl2 and lithium chloride (0.021 g, 0.50 mmol), and a 30% solution of H2O2 (0.1 mL, 1 mmol) was added. The reaction mixture was stirred at room temperature for 7 days. The color of the solution changed from initial orange to deep red after 2 days and then to orange–red. MnO2 (2 g) was added, the solution was stirred for 0.5 h, filtered, and MnO2 was washed with acetone. After concentrating the filtrate, distilled water (6 mL) was added until it became cloudy. A deep-red-colored oil formed with a cloudy solution. The red oil was separated and dissolved in acetone, and crystallization from acetone/hexane at −10 °C produced deep-red-colored blocks of the platinum(IV) species, 2·H2O(red) (0.1637 g, yield = 50%). The cloudy solution was evaporated until dryness and then dissolved again in acetone; crystallization from acetone/hexane produced the mononuclear platinum(IV) species golden 2·H2O in a 14% yield, identified by X-ray crystallography.
WARNING: Concentrated H2O2 in the acetone in presence of an acid catalyst can form the shock and friction-sensitive explosive triacetone triperoxide (TATP). MnO2 was used to decompose any residual H2O2 catalytically before workup [77].
(a) cis, cis, trans- [Pt{(p-BrC6F4)NCH2CH2NEt2}Cl(py)(OH)2].H2O 2·H2O(red): Metallic deep-red-colored blocks. (0.164 g, 50% yield). M.P. = 172 °C. (dec). Elemental analysis calcd for C17H23Br1Cl1F4N3Pt1O3 (M = 702.2): C, 29.01%; H, 3.29%; N, 5.97%. Found: C, 29.28%; H, 3.16%; N, 6.03%.
*Both PtII (1H) and PtIV 2 were observed in the solution in a 1:1 ratio.
19F NMR (CD3(CO)2): PtII, 1H: −148.16 [m, 2 F, F 2,6], −138.24 [m, 2 F, F 3,5]; PtIV, 2: −138.34 [m, 2 F, F 3,5], −140.64 [m, 2 F, F 2, 6].1H NMR (CD3(CO)2): 1.23 [t, 6H, 3JH,H 7 Hz, 4JH,H 3Hz, NCH2CH3 (2)], 1.56 [t, 6H, 3JH,H 7 Hz, 4JH,H 3Hz, NCH2CH3 (1H)], 2.30 [m, 2H, CH2NEt2 (2)], 2.77 [m, 2H, NCHAHBCH3 (1H)], 3.00 [m, 2H, NCHAHBCH3, (2)], 3.13 [m, 2H, NCHBHACH3 (2)], 3.33 [m, 2H, CH2N(p-BrC6F4) (2)], 3.43 [m, 2H, NCHBHACH3 (1H)], 3.75 [d with 195Pt satellites, 3JH,H 3.45 Hz, 3JH,Pt 34 Hz, 1H, CHNEt2 (1H)], 4.03 [m, 2H, not exchangeable with D2O], 6.07 [m with 195Pt satellites, 3JH,Pt 50 Hz, 1H, CHN(p-BrC6F4) (1H)], 7.19 [m, 2H, H3,5 (py)], (1H)] 7.33 [t, 3JH,H 7 Hz, 2H, H3,5 (py) (2)]], 7.74 [tt,3JH,H 7.8 Hz, 4JH,H 1Hz, 1H, H4 (py) (1H)], 7.86 [t, 3JH,H 7.7 Hz, 1H, H4 (py) (2)], 8.42 [d with 195Pt satellites, 3JH,H 5.6 Hz, 3JH,Pt 35 Hz, 2H, H2,6 (py) (1H)], 8.98 [d with Pt satellites, 3JH,H 5.6 Hz, 3JH,Pt 35 Hz, 2H, H 2,6 (py) (2)]. IR: 3549m, 3050w, 2964w, 2929w, 2871w, 2372w, 2108w, 1922w, 1704w, 1655s, 1620s, 1475s, 1451w, 1374m, 1287w, 1261w, 1223m, 1141s, 1061m, 1014w, 968s, 917m, 834w, 820s, 763s, 741s, 694s, 638w cm−1. (ESI m/z (+ve) are given in SI).

3.4.3. Oxidation of 1 with Excess H2O2 in the Presence of Tetrabutylammonium Chloride (TBACl)

In a solution of 1 (0.314 g, 0.48 mmol) in 20 mL CH2Cl2, 0.127 g TBACl (0.48 mmol) in 2 mL of CH2Cl2 and (0.1 mL, 1.0 mmol) of 30% solution of H2O2 were added. The solution was heated at near refluxing temperature for 6 h and then stirred at room temperature for 4 days. The color of the solution changed from yellow to dark orange, but not deep red; MnO2 was added at this stage. After filtration, the solution was concentrated to 5 mL, and a deep-red-colored oil formed when hexane (6 mL) was added. This mixture was cooled at −10 °C. Deep-red-colored blocks of the platinum(IV) complex 3 were collected by filtration and then air-dried. Some 2·H2O(gold) was collected from the filtrate with a few pale-yellow crystals of [NBu4][PtCl3(py)] characterized by single-crystal X-ray crystallography only.
(a) cis, cis, trans- [{Pt{(p-BrC6F4)NCH2CH2NEt2}Cl(py)(OH)2}2].CH2Cl2, 3·0.5CH2Cl2: Metallic red-colored blocks. (0.152.9g, 49% crystal yield). Elemental analysis calcd for C35H44Cl4F8N6Pt2Br2O4 (M = 1456.56): C, 28.86%; H, 3.04%; N, 5.77%. Found: C, 29.05%; H, 3.13%; N, 5.65%.
*In the solution PtII (1H and 1Cl) and PtIV are present. The ratio of platinum(IV), 1H, and 1Cl is 1:2:0.7, respectively. Most of the NMR resonances of 1H and 1Cl are overlapped.
19F NMR (CD3(CO)2): 1H: −148.61 [m, 2 F, F 2, 6], −137.96 [m, 2 F, F 3,5]; 1Cl: −148.46 [m, 2 F, F 2, 6], −137.27 [m, 2 F, F 3,5]; PtIV,(3): −137.63 [m, 2 F, F 3,5], −142.25 [m, 2 F, F 2,6]. 1H NMR (CD3(CO)2): 1.26 [t, 6H, 3JH,H 7 Hz, 4JH,H 3Hz, NCH2CH3, (3)], 1.61 [t, 6H, 3JH,H 7 Hz, 4JH,H 3Hz, NCH2CH3, (1H+1Cl)], 2.30 [m, 2H, CH2NEt2, (3)], 2.70 [m, 2H, NCHAHBCH3, (1H+1Cl)], 3.00 [m, 2H, NCHAHBCH3 and 2H, NCHBHACH3,(3)], 3.47 [m, 2H, NCHBHACH3 and 2H, CH2N(p-BrC6F4), (3)], 3.68 [d with 195Pt satellites, 3JH,H 3.45 Hz, 3JH,Pt 34 Hz, 1H, CHNEt2, (1H)], 4.03 [m, 2H, not exchangeable with D2O], 6.01 [m with 195Pt satellites, 3JH,Pt 50 Hz, 1H, CHN(p-BrC6F4), (1H)], 6.43 [t, 0.5 H, CHNEt2, (1Cl)], 6.47 [t, 0.5 H, CHNEt2, (1Cl)], 7.04 [m, 2H, H 3, 5 (py), (1H+1Cl)], 7.19 [t, 3JH,H 7 Hz, 2H, H 3, 5 (py), (3)], 7.59 [tt,3JH,H 7.8 Hz, 4JH,H 1Hz, 1H, H4 (py), (1H+1Cl)], 7.72 [t, 3JH,H 7.7 Hz, 1H, H4 (py), (3)], 8.39 [with 195Pt satellites, 3JH,H 5.6 Hz, 3JH,Pt 35 Hz, 2H, H2,6 (py), (1H+1Cl)], 8.98 [d with 195Pt satellites, 3JH,H 5.6 Hz, 3JH,Pt 35 Hz, 2H, H2,6 (py), (3)]. IR: 3652m, 3388br, 2963w, 2875w, 1923w, 1704w, 1655s, 1620s, 1475s, 1451w, 1374m, 1287w, 1261w, 1223m, 1141s, 1061m, 1014w, 968s, 917m, 834w, 820s, 763s, 741s, 694s, 638w cm−1.
The data for 1H and 1Cl agree with that reported [47].

4. Conclusions

The oxidation of [Pt{(p-BrC6F4)NCH2CH2NEt2}Cl(py)], 1 by limited H2O2 at room temperature produced dihydroxidoplatinum(IV) complexes [PtIV{(p-BrC6F4)NCH2CH2NEt2}Cl(OH)2(py)].H2O, 2·H2O, and [PtIV{(p-BrC6F4)NCH2CH2NEt2}Cl(OH)2(py)].0.5CH2Cl2, 3·0.5CH2Cl2, depending on the solvent system used. 2·H2O was obtained as two different colored crystals, red and gold. Identical unit cells and X-ray powder diffraction patterns generated from their X-ray crystal structures verify that they have the same structure. As the initial preparation of 2·H2O(gold) was accompanied by the formation of the PtII complex with the oxidized ligand [Pt{(p-BrC6F4)NCH=CHNEt2}Cl(py)] 1H, different conditions, including changes in solvents and the addition of chloride salts, were used to make the reactions more selective and produce higher yields in preparations of 2·H2O(red) and 3·0.5CH2Cl2. These PtIV compounds show reductive dehydration, that is, reduction of PtIV to PtII, accompanied by oxidation of the ligand over time in the solid state, as determined by X-ray powder diffraction and the separation of crystals, and in solution as evident from NMR and Mass spectra. The main product is 1H, but co-crystallized 1H/1Cl (1Cl = [Pt(p-BrC6F4)NCH=C(Cl)NEt2}Cl(py)]) was obtained in some cases. This reveals that the PtIV complexes are precursors in the formation of the oxidized ligand species 1H and 1Cl. The rate of reductive dehydration is faster for 2·H2O(gold) than for 2·H2O(red). Vigorous oxidation conditions lead to complexes of the oxidized ligand [47], whereas the mild conditions currently used provide access to PtIV. As a wide range of Class 2 organoamidoplatinum(II) compounds are known [46], access to many derived PtIV compounds is possible, and some of which may have greater stability than 2·H2O and 3·0.5CH2Cl2.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules28176402/s1, S1. PtIV data [Table S1: Selected bond angles for compounds 2·H2O(gold) and 3·0.5CH2Cl2; Figure S1: Comparison of Powder XRD patterns calculated from single-crystal X-ray diffraction data of gold and 2·H2O(red) presented in the respective colors. Table S2: Selected bond angles for compound 2·H2O(red).] S2. [NBu4][PtCl3(py)] Data [Figure S2: Molecular structure of [NBu4][PtCl3(py)], showing 50% thermal ellipsoids. Table S3: Crystallographic data for the molecular structures of [NBu4][PtCl3(py)]; Table S4: Selected bond lengths and bond angles of [NBu4][PtCl3(py)].] S3. Variable temperature NMR spectra [Figure S3: 19F NMR spectra obtained for 2·H2O(red) over the temperature range of 25 °C to −60 °C. Figure S4: 1H NMR spectra obtained for 2·H2O(red) over the temperature range of 25 °C to −60 °C, showing 6–9 ppm region. Figure S5: 1H NMR spectra obtained for 2·H2O(red) over the temperature range from 25 °C to −60 °C, showing 1–4.5 ppm region. Figure S6: 19F NMR spectra obtained for 2·H2O(red) at 25°C and 50°C.] S4. PXRD data [Figure S7: Normalized powder X-ray diffraction data for bulk samples of 2·H2O(gold) and 2·H2O(red), shown in their respective colors. Figure S8: Normalized powder X-ray diffraction data for bulk sample of 2·H2O(red) with normalized powder X-ray diffraction data generated from the single crystal of 1H and 2·H2O(red); Figure S9: Normalized powder X-ray diffraction data for bulk sample of 2·H2O(gold) with normalized powder X-ray diffraction data generated from the single crystals of 1H and 2·H2O(gold) [78,79,80,81].] S5. Isolation of PtIV from the solution of an aged bulk sample [Table S5 Unit cell parameters for 1H and co-crystallized 1(H/Cl) collected from the bulk sample of 2·H2O(red) and 2·H2O(gold). Table S6: Unit cell parameters for PtIV 2·H2O(red)ʹ, co-crystallized 1(H/Cl) and [NBu4][PtCl3(py)] isolated from the solution of an aged sample of 3·0.5CH2Cl2. S6. Electrospray MS measurements. S7. IR Spectroscopy data.

Author Contributions

Conceptualization, G.B.D. and A.M.B.; Synthesis, spectroscopy, characterization, original draft, R.O.; X-ray crystallography, R.O.; Supervision and editing, G.B.D., A.M.B. and P.C.J.; Rewriting and editing, G.B.D. and R.O. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Australian Research Council (grant DP120101470) and the Australian Postgraduate Award.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Crystal data can be obtained from Cambridge Crystallographic Data Centre as supplementary number CCDC 2272032 for 2·H2O(gold), 2272033 for 2·H2O(red), 2272037 for 3, and 2280550 for [NBu4][PtCl3(py)]. Copies of the data can be obtained free of charge at www.ccdc.cam.ac.uk/data_request/cif (accessed on 31 July 2023).

Acknowledgments

A.M.B. gratefully acknowledges financial support from the Australian Research Council (grant DP120101470). R.O. thanks the Australian Government for the provision of an Australian Postgraduate Award. X-ray crystallography data collection in this research was undertaken on the MX1 beamline at the Australian Synchrotron, which is a part of ANSTO [82].

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds are available from the authors.

References

  1. Rosenberg, B.; Van Camp, L.; Krigas, T. Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature 1965, 205, 698–699. [Google Scholar] [CrossRef] [PubMed]
  2. Johnstone, T.C.; Park, G.Y.; Lippard, S.J. Understanding and improving platinum anticancer drugs—Phenanthriplatin. Anticancer Res. 2014, 34, 471–476. [Google Scholar] [PubMed]
  3. Wong, E.; Giandomenico, C.M. Current status of platinum-based antitumor drugs. Chem. Rev. 1999, 99, 2451–2466. [Google Scholar] [CrossRef] [PubMed]
  4. Wang, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005, 4, 307–320. [Google Scholar] [PubMed]
  5. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7, 573–584. [Google Scholar] [CrossRef] [PubMed]
  6. Fricker, S.P. Metal based drugs: From serendipity to design. Dalton Trans. 2007, 4903–4917. [Google Scholar] [CrossRef] [PubMed]
  7. Wheate, N.J.; Walker, S.; Craig, G.E.; Oun, R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010, 39, 8113–8127. [Google Scholar] [CrossRef]
  8. Farrell, N.P. Platinum formulations as anticancer drugs clinical and pre-clinical studies. Curr. Top. Med. Chem. 2011, 11, 2623–2631. [Google Scholar] [CrossRef]
  9. Stewart, D.J. Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol. 2007, 63, 12–31. [Google Scholar]
  10. Rabik, C.A.; Dolan, M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 2007, 33, 9–23. [Google Scholar] [CrossRef]
  11. Weiss, R.B.; Christian, M.C. New cisplatin analogs in development—A Review. Drugs 1993, 46, 360–377. [Google Scholar] [CrossRef] [PubMed]
  12. Hartmann, J.T.; Lipp, H.P. Toxicity of platinum compounds. Expert Opin. Pharmacother. 2003, 4, 889–901. [Google Scholar] [CrossRef] [PubMed]
  13. Abu-Surrah, A.S.; Kettunen, M. Platinum group antitumor chemistry: Design and development of new anticancer drugs complementary to cisplatin. Curr. Med. Chem. 2006, 13, 1337–1357. [Google Scholar] [CrossRef] [PubMed]
  14. Todd, R.C.; Lippard, S.J. Inhibition of transcription by platinum antitumor compounds. Metallomics 2009, 1, 280–291. [Google Scholar] [CrossRef]
  15. Klein, A.V.; Hambley, T.W. Platinum drug distribution in cancer cells and tumors. Chem. Rev. 2009, 109, 4911–4920. [Google Scholar] [CrossRef] [PubMed]
  16. Piccart, M.; Lamb, H.; Vermorken, J.B. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann. Oncol. 2001, 12, 1195–1203. [Google Scholar]
  17. Hambley, T.W. The influence of structure on the activity and toxicity of Pt anticancer drugs. Coord. Chem. Rev. 1997, 166, 181–223. [Google Scholar] [CrossRef]
  18. Gibson, D. Platinum(iv) anticancer prodrugs—Hypotheses and facts. Dalton Trans. 2016, 45, 12983–12991. [Google Scholar] [CrossRef]
  19. Lee, Y.-A.; Lee, S.S.; Kim, K.M.; Lee, C.O.; Sohn, Y.S. Synthesis and oral antitumor activity of tetrakis(carboxylato)platinum(IV) complexes. J. Med. Chem. 2000, 43, 1409–1412. [Google Scholar] [CrossRef]
  20. Barbanente, A.; Gandin, V.; Ceresa, C.; Marzano, C.; Ditaranto, N.; Hoeschele, J.D.; Natile, G.; Arnesano, F.; Pacifico, C.; Intini, F.P.; et al. Improvement of Kiteplatin efficacy by a benzoato Pt(IV) prodrug suitable for oral administration. Int. J. Mol. Sci. 2022, 23, 7081. [Google Scholar] [CrossRef]
  21. Galanski, M.; Keppler, B.K. Searching for the magic bullet: Anticancer platinum drugs which can be accumulated or activated in the tumor tissue. Anticancer Agents Med. Chem. 2007, 7, 55–73. [Google Scholar] [CrossRef] [PubMed]
  22. Hall, M.D.; Mellor, H.R.; Callaghan, R.; Hambley, T.W. Basis for design and development of platinum(IV) anticancer complexes. J. Med. Chem. 2007, 50, 3403–3411. [Google Scholar] [CrossRef] [PubMed]
  23. Harrap, K.R.; Kelland, L.R.; Jones, M.; Goddard, P.M.; Orr, R.M.; Morgan, S.E.; Murrer, B.A.; Abrams, M.J.; Giandomenico, C.M.; Cobbleigh, T. Platinum coordination complexes which circumvent cisplatin resistance. Adv. Enzym. Res. 1991, 31, 31–43. [Google Scholar] [CrossRef] [PubMed]
  24. Albert, A. Chemical aspects of selective toxicity. Nature 1958, 182, 421–423. [Google Scholar] [CrossRef] [PubMed]
  25. Xiao, H.; Song, H.; Yang, Q.; Cai, H.; Qi, R.; Yan, L.; Liu, S.; Zheng, Y.; Huang, Y.; Liu, T.; et al. A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance. Biomaterials 2012, 33, 6507–6519. [Google Scholar] [CrossRef]
  26. Hall, M.D.; Hambley, T.W. Platinum(IV) antitumour compounds: Their bioinorganic chemistry. Coord. Chem. Rev. 2002, 232, 49–67. [Google Scholar] [CrossRef]
  27. Yao, H.; Wang, Z.; Wang, N.; Deng, Z.; Liu, G.; Zhou, J.; Chen, S.; Shi, J.; Zhu, G. Enhancing circulation and tumor accumulation of carboplatin via an erythrocyte-anchored prodrug strategy. Angew. Chem. Int. Ed. 2022, 61, e202203838. [Google Scholar] [CrossRef]
  28. Ellis, L.T.; Er, H.M.; Hambley, T.W. The influence of the axial ligands of a series of platinum(IV) anticancer complexes on their reduction to platinum(II) and reaction with DNA. Aust. J. Chem. 1995, 48, 793–806. [Google Scholar] [CrossRef]
  29. Chaney, S.G.; Wyrick, S.; Till, G.K. In vitro biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma. Cancer Res. 1990, 50, 4539–4545. [Google Scholar]
  30. Poon, G.K.; Raynaud, F.I.; Mistry, P.; Odell, D.E.; Kelland, L.R.; Harrap, K.R.; Barnard, C.F.; Murrer, B.A. Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization-mass spectrometry. J. Chromatogr. 1995, 712, 61–66. [Google Scholar] [CrossRef]
  31. Choi, S.; Filloto, C.; Bisanzo, M.; Delaney, S. Reduction and anticancer activity of Platinum(IV) complexes. Inorg. Chem. 1998, 37, 2500–2504. [Google Scholar] [CrossRef]
  32. Huang, J.; Ding, W.; Zhu, X.; Li, B.; Zeng, F.; Wu, K.; Wu, X.; Wang, F. Ligand evolution in the photoactivatable platinum(IV) anticancer prodrugs. Front. Chem. 2022, 10, 876410. [Google Scholar] [CrossRef] [PubMed]
  33. Spector, D.; Pavlov, K.; Beloglazkina, E.; Krasnovskaya, O. Recent advances in light-controlled activation of Pt(IV) prodrugs. Int. J. Mol. Sci. 2022, 23, 14511. [Google Scholar] [CrossRef]
  34. Chen, Q.; Yang, Y.; Lin, X.; Ma, W.; Chen, G.; Li, W.; Wang, X.; Yu, Z. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance. Chem. Comm. 2018, 54, 5369–5372. [Google Scholar] [CrossRef] [PubMed]
  35. Xie, P.; Jin, Q.; Li, Y.; Zhang, J.; Kang, X.; Zhu, J.; Mao, X.; Cao, P.; Liu, C. Nanoparticle delivery of a triple-action Pt(IV) prodrug to overcome cisplatin resistance via synergistic effect. Biomater. Sci. 2022, 10, 153–157. [Google Scholar] [CrossRef] [PubMed]
  36. Gibson, D. Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end? J. Inorg. Biochem. 2021, 217, 111353. [Google Scholar] [CrossRef]
  37. Sinisi, M.; Intini, F.P.; Natile, G. Dependence of the reduction products of platinum(IV) prodrugs upon the configuration of the substrate, bulk of the carrier ligands, and nature of the reducing agent. Inorg. Chem. 2012, 51, 9694–9704. [Google Scholar] [CrossRef]
  38. Nemirovski, A.; Vinograd, I.; Takrouri, K.; Mijovilovich, A.; Rompel, A.; Gibson, D. New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugs. Chem. Commun. 2010, 46, 1842–1844. [Google Scholar] [CrossRef]
  39. Hambley, T.W. New approaches to platinum anti-cancer drugs. Chem. Aust. 1991, 58, 154–156. [Google Scholar]
  40. Lovejoy, K.S.; Lippard, S.J. Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting. Dalton Trans. 2009, 10651–10659. [Google Scholar] [CrossRef]
  41. Cleare, M.J.; Hoeschele, J.D. Studies on the antitumor activity of group VIII transition metal complexes. Part I. Platinum (II) complexes. Bioinorg. Chem. 1973, 2, 187–210. [Google Scholar] [CrossRef]
  42. Farrell, N. Metal Ions in Biological Systems, 1st ed.; CRC Press: Boca Raton, FL, USA, 2004; Volume 42, p. 46. [Google Scholar]
  43. Wheate, N.J.; Collins, J.G. Multi-nuclear platinum drugs: A new paradigm in chemotherapy. Curr. Med. Chem. Anticancer Agents 2005, 5, 267–279. [Google Scholar] [CrossRef] [PubMed]
  44. Wheate, N.J.; Collins, J.G. Multi-nuclear platinum complexes as anticancer drugs. Coord. Chem. Rev. 2003, 241, 133–145. [Google Scholar] [CrossRef]
  45. Webster, L.K.; Deacon, G.B.; Buxton, D.P.; Hillcoat, B.L.; James, A.M.; Roos, I.A.G.; Thomson, R.J.; Wakelin, L.P.G.; Williams, T.L. Cis-bis(pyridine)platinum(II) organoamides with unexpected growth-inhibition properties and antitumor-activity. J. Med. Chem. 1992, 35, 3349–3353. [Google Scholar] [CrossRef] [PubMed]
  46. Talarico, T.; Phillips, D.R.; Deacon, G.B.; Rainone, S.; Webster, L.K. Activity and DNA binding of new organoamidoplatinum (II) complexes. Investig. New Drugs 1999, 17, 1–15. [Google Scholar] [CrossRef]
  47. Ojha, R.; Mason, D.; Forsyth, C.M.; Deacon, G.B.; Junk, P.C.; Bond, A.M. Diverse and unexpected outcomes from oxidation of the platinum(II) anticancer agent [Pt{(p-BrC6F4)NCH2CH2NEt2}Cl(py)] by hydrogen peroxide. J. Inorg. Biochem. 2021, 218, 111360. [Google Scholar] [CrossRef]
  48. Masztafiak, J.; Nogueira, J.; Lipiec, L.; Kwiatek, W.; Wood, B.; Deacon, G.B.; Kayser, Y.; Fernandes, D.; Pavliuk, M.; Szlachetko, J.; et al. Direct determination of metal complexes interation with DNA by atomic telemetry and multiscale molecular dynamics. J. Phys. Chem. Lett. 2017, 8, 805–811. [Google Scholar] [CrossRef]
  49. Shaw, P.A.; Clarkson, G.J.; Rourke, J.P. Long-lived five-coordinate platinum(IV) intermediates: Regiospecific c–c coupling. Organometallics 2016, 35, 3751–3762. [Google Scholar] [CrossRef]
  50. Twigg, M.V. Higher Oxidation State Organopalladium and Platinum Chemistry. Platin. Met. Rev. 2012, 56, 104–109. [Google Scholar] [CrossRef]
  51. Canty, A.J.; Hoare, J.L.; Davies, N.W.; Traill, P.R. Synthesis and decomposition behavior of Pallada(IV)cyclopentane complexes. Organometallics 1998, 17, 2046–2051. [Google Scholar] [CrossRef]
  52. Canty, A.J. Development of organopalladium(IV) chemistry: Fundamental aspects and systems for studies of mechanism in organometallic chemistry and catalysis. Acc. Chem. Res. 1992, 25, 83–90. [Google Scholar] [CrossRef]
  53. Topczewski, J.J.; Sanford, M.S. Carbon–hydrogen (C–H) bond activation at Pd(IV): A frontier in c–h functionalization catalysis. Chem. Sci. 2015, 6, 70–76. [Google Scholar] [CrossRef] [PubMed]
  54. Guo, S.-X.; Mason, D.N.; Turland, S.A.; Lawrenz, E.T.; Kelly, L.C.; Fallon, G.D.; Gatehouse, B.M.; Bond, A.M.; Deacon, G.B.; Battle, A.R.; et al. Systematic differences in electrochemical reduction of the structurally characterized anticancer platinum(IV) complexes [Pt{((p-HC6F4)NCH2)2}-(pyridine)2Cl2], [Pt{((p-HC6F4)NCH2)2}(pyridine)2(OH)2], and [Pt{((p-HC6F4)NCH2)2}(pyridine)2(OH)Cl]. J. Inorg. Biochem. 2012, 115, 226–239. [Google Scholar] [CrossRef] [PubMed]
  55. Taylor, R.A.; Law, D.J.; Sunley, G.J.; White, A.J.P.; Britovsek, G.J.P. Hydrogen bonding directs the H2O2 oxidation of platinum(ii) to a cis-dihydroxo platinum(iv) complex. Chem. Commun. 2008, 2800–2802. [Google Scholar] [CrossRef]
  56. Shamsuddin, S.; Santillan, C.C.; Stark, J.L.; Whitmire, K.H.; Siddik, Z.H.; Khokhar, A.R. Synthesis, characterization, and antitumor activity of new platinum(IV) trans-carboxylate complexes: Crystal structure of [Pt(cis-1,4-DACH)trans-(acetate)2Cl2]. J. Inorg. Biochem. 1998, 71, 29–35. [Google Scholar] [CrossRef]
  57. Lee, Y.-A.; Ho Yoo, K.; Jung, O.-S. Oxidation of Pt(II) to Pt(IV) complex with hydrogen peroxide in glycols. Inorg. Chem. Commun. 2003, 6, 249–251. [Google Scholar] [CrossRef]
  58. Canil, G.; Braccini, S.; Marzo, T.; Marchetti, L.; Pratesi, A.; Biver, T.; Funaioli, T.; Chiellini, F.; Hoeschele, J.D.; Gabbiani, C. Photocytotoxic Pt(iv) complexes as prospective anticancer agents. Dalton Trans. 2019, 48, 10933–10944. [Google Scholar] [CrossRef]
  59. Abrams, M.J.; Giandomenico, C.M.; Murrer, B.A.; Vollano, J.F. Pt(IV) Complexes as Anti-Tumor Agents. U.S. Patent Application No. 5,244,919, 1 July 1991. [Google Scholar]
  60. Giandomenico, C.M.; Abrams, M.J.; Murrer, B.A.; Vollano, J.F.; Rheinheimer, M.I.; Wyer, S.B.; Bossard, G.E.; Higgins, J.D. Carboxylation of kinetically inert platinum(iv) hydroxy complexes. an entree into orally active platinum(iv) antitumor agents. Inorg. Chem. 1995, 34, 1015–1021. [Google Scholar] [CrossRef]
  61. Ojha, R.; Boas, J.F.; Deacon, G.B.; Junk, P.C.; Bond, A.M. EPR spectroscopic characterization of a monomeric PtIII species produced via electrochemical oxidation of the anticancer compound trans-[PtII{(p-HC6F4)NCH2CH2NEt2}Cl(py)]. J. Inorg. Biochem. 2016, 162, 194–200. [Google Scholar] [CrossRef]
  62. Ojha, R.; Nafady, A.; Shiddiky, M.J.A.; Mason, D.; Boas, J.F.; Torriero, A.A.J.; Bond, A.M.; Deacon, G.B.; Junk, P.C. Conditions Favoring the Formation of Monomeric PtIII Derivatives in the Electrochemical Oxidation of trans-[PtII{(p-BrC6F4)NCH2CH2NEt2}Cl(py)]. ChemElectroChem 2015, 2, 1048–1061. [Google Scholar] [CrossRef]
  63. Kauffman, G.B.; Cowan, D.O.; Slusarczuk, G.; Kirschner, S. cis- and trans-Dichlorodiammineplatinum(II). In Inorganic Syntheses; McGraw-Hill Book Company, Inc.: New York, NY, USA, 1963; Volume 7, pp. 239–245. [Google Scholar]
  64. Wilson, J.J.; Lippard, S.J. Synthetic methods for the preparation of platinum anticancer complexes. Chem. Rev. 2014, 114, 4470–4495. [Google Scholar] [CrossRef]
  65. Cox, L.E.; Peters, D.G.; Wehry, E.L. Photoaquation of hexachloroplatinate (IV). J. Inorg. Nucl. Chem. 1972, 34, 297–305. [Google Scholar] [CrossRef]
  66. Dunham, S.O.; Larsen, R.D.; Abbott, E.H. Nuclear Magnetic Resonance investigation of the hydrogen peroxide oxidation of Platinum(II) complexes. crystal and molecular structures of sodium írans-dihydroxobis(malonato)plátinate(iv) hexahydrate and sodium frans-dihydroxobis(oxalato)platinate(iv) hexahydrate. Inorg. Chem. 1993, 32, 2049–2055. [Google Scholar]
  67. Murray, P.; Koch, K.R.; van Eldik, R. Mechanism of tetrachloroplatinate(ii) oxidation by hydrogen peroxide in hydrochloric acid solution. Dalton Trans. 2014, 43, 6308–6314. [Google Scholar] [CrossRef] [PubMed]
  68. Greenwood, N.N.; Earnshaw, A. Chemistry of the Elements, 2nd ed.; Butterworth-Heinemann: Oxford, UK, 1997. [Google Scholar]
  69. Deacon, G.B.; Patrick, J.M.; Skelton, B.W.; Thomas, N.C.; White, A.H. Ruthenium carbonyl complexes. III. Peparations, properties and structures of Dicarbonyl- and Monocarbonyl-(2,2′:6′,2″-terpyridyl)ruthenium(II) complexes. Aust. J. Chem. 1984, 37, 929–945. [Google Scholar] [CrossRef]
  70. Ojha, R.; Junk, P.C.; Deacon, G.B.; Bond, A.M. A supramolecular approach to the examination of the structures of some anticancer organoamidoplatinum(II) complexes. Supramol. Chem. 2018, 30, 418–424. [Google Scholar] [CrossRef]
  71. Nakamoto, K. Infra-Red and Raman Spectra of Inorganic Coordination Compounds, 4th ed.; John Wiley and Sons: New York, NY, USA, 1986. [Google Scholar]
  72. McPhillips, T.M.; McPhillips, S.E.; Chiu, H.J.; Cohen, A.E.; Deacon, A.M.; Ellis, P.J.; Garman, E.; Gonzalez, A.; Sauter, N.K.; Phizackerley, R.P.; et al. Blu-Ice and the Distributed Control System: Software for data acquisition and instrument control at macromolecular crystallography beamlines. J. Synch. Rad. 2002, 9, 401–406. [Google Scholar] [CrossRef]
  73. Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallogr. 1993, 26, 795–800. [Google Scholar] [CrossRef]
  74. Sheldrick, G.M. A short history of SHELX. Acta Crystallogr. Sect. A 2008, 64, 112–122. [Google Scholar] [CrossRef]
  75. Bruker AXS; APEX2 v 2.0. Bruker AXS Inc.: Madison, WI, USA, 2005.
  76. Barbour, L.J. X-Seed—A software tool for supramolecular crystallography. J. Supramol. Chem. 2001, 1, 189–191. [Google Scholar] [CrossRef]
  77. Broughton, D.B.; Wentworth, R.L.; Laing, M.E. Mechanism of decomposition of hydrogen peroxide solutions with manganese dioxide II. J. Am. Chem. Soc. 1947, 69, 744–747. [Google Scholar] [CrossRef] [PubMed]
  78. Kukushkin, V.Y.; Belskii, V.; Aleksandrova, E.; Pankova, E.; Konovalov, V.; Yakovlev, V.; Moiseev, A. Unusual Redox-Pairing of Acetoxime Ligands in Platinum Complex. Zhurnal Obs. Khimii 1991, 61, 318–328. [Google Scholar]
  79. Melanson, R.; Rochon, F.D. The crystal structure of potassium trichloro(2,6-lutidine)platinum(II). Can. J. Chem. 1976, 54, 1002–1006. [Google Scholar] [CrossRef]
  80. Cingi Biagini, M.; Ferrari, M.; Lanfranchi, M.; Marchiò, L.; Angela Pellinghelli, M. Chirality in mononuclear square planar complexes. J. Chem. Soc. Dalton Trans. 1999, 1575–1580. [Google Scholar] [CrossRef]
  81. Flack, H.D. On Enantiomorph-Polarity Estimation. Acta Cryst. 1983, A39, 876–881. [Google Scholar] [CrossRef]
  82. Cowieson, N.P.; Aragao, D.; Clift, M.; Ericsson, D.J.; Gee, C.; Harrop, S.J.; Mudie, N.; Panjikar, S.; Price, J.R.; Riboldi-Tunnicliffe, A.; et al. MX1: A bending-magnet crystallography beamline serving both chemical and macromolecular crystallography communities at the Australian Synchrotron. J. Synchrotron. Radiat. 2015, 22, 187–190. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Class 1 and Class 2 organoamidoplatinum(II) compounds.
Figure 1. Class 1 and Class 2 organoamidoplatinum(II) compounds.
Molecules 28 06402 g001
Scheme 1. A comparison of the products obtained from the H2O2 oxidation of 1 in acetone, with heating (top blue) and at room-temperature (bottom red) conditions.
Scheme 1. A comparison of the products obtained from the H2O2 oxidation of 1 in acetone, with heating (top blue) and at room-temperature (bottom red) conditions.
Molecules 28 06402 sch001
Scheme 2. Oxidation of 1 with H2O2 under mild conditions showing major products.
Scheme 2. Oxidation of 1 with H2O2 under mild conditions showing major products.
Molecules 28 06402 sch002
Figure 2. Molecular structures of PtIV complexes (a) 2·H2O(gold) with intramolecular H-bonding; (b) crystal packing in 2·H2O(gold) showing intermolecular H-bonding; and (c) 2·H2O(red), with 50% thermal ellipsoids.
Figure 2. Molecular structures of PtIV complexes (a) 2·H2O(gold) with intramolecular H-bonding; (b) crystal packing in 2·H2O(gold) showing intermolecular H-bonding; and (c) 2·H2O(red), with 50% thermal ellipsoids.
Molecules 28 06402 g002
Figure 3. (a) Molecular structure of PtIV complex 3·0.5CH2Cl2, showing 50% thermal ellipsoids. (b) Crystal packing in 3·0.5CH2Cl2, showing inter- and intramolecular H-bonding.
Figure 3. (a) Molecular structure of PtIV complex 3·0.5CH2Cl2, showing 50% thermal ellipsoids. (b) Crystal packing in 3·0.5CH2Cl2, showing inter- and intramolecular H-bonding.
Molecules 28 06402 g003
Table 1. Quantities of reagents and product yields (crystalline) for the oxidation of 1 with 30% H2O2 reactions performed at room temperature.
Table 1. Quantities of reagents and product yields (crystalline) for the oxidation of 1 with 30% H2O2 reactions performed at room temperature.
CompoundCl SourceH2O2SolventTimeProducts with Yields
1
(1.0 mmol)
none2.0 mmolCH3COCH312 d1H = 1.4%,
H2O(gold) = 25%;
1H0.251Br0.75 = 7%
1
(0.5 mmol)
LiCl
(0.5 mmol)
1.0 mmol* CH2Cl27 dH2O(red) = 50%,
H2O(gold) = 14%
1
(0.48 mmol)
NBu4Cl
(0.48 mmol)
1.0 mmol* CH2Cl24 d3·0.5CH2Cl2 = 49%,
H2O(gold) = 10%
* workup differs (see experimental).
Table 2. Crystallographic data for the molecular structures of 2·H2O(gold), 2·H2O(red), and 3·0.5CH2Cl2.
Table 2. Crystallographic data for the molecular structures of 2·H2O(gold), 2·H2O(red), and 3·0.5CH2Cl2.
2·H2O(gold)2·H2O(red)3·0.5CH2Cl2
Empirical formulaC17H19BrClF4N3O3PtC17H19BrClF4N3O3PtC17.5H22BrCl2F4N3O2Pt
Formula weight703.83703.83728.28
Crystal systemMonoclinicMonoclinicMonoclinic
Space groupC2/cCcC2/c
a (Å)19.719(4)19.6389(16)14.948(3)
b (Å)13.357(3)13.3360(11)14.302(3)
c (Å)16.946(3)16.9327(13)21.743(4)
α (°)909090
β (°)105.29(3)104.857(2)104.53(3)
γ (°)909090
vol (Å3)4305.4(16)4286.5(6)4499.7(17)
Z888
ρ (calcd) (g/cm3)2.1722.1692.150
µ (mm−1)8.5578.5948.303
F (000)2688.02656.02776.0
Reflections collected/unique31,692/507135,311/12,15840,998/6383
Rint0.10160.05370.0504
2θmax (°)56.3361.263.5
Goodness-of-fit on F21.2871.0441.060
R1 indices [I ≥ 2σ (I)]0.07120.03870.0342
wR2 indices [I ≥ 2σ (I)]0.14310.06340.0841
Flack parametern/a0.398(5)n/a
n/a = not applicable.
Table 3. Selected bond lengths for compounds 2·H2O(gold), 2·H2O(red) (given for both molecules in asymmetric units), and 3·0.5CH2Cl2.
Table 3. Selected bond lengths for compounds 2·H2O(gold), 2·H2O(red) (given for both molecules in asymmetric units), and 3·0.5CH2Cl2.
Bond2·H2O(gold)
C17H23BrClF4N3O3Pt
(Å)
2·H2O(red)
C17H23BrClF4N3O3Pt
(Molecules A and B in Asymmetric Unit) (Å)
3·0.5CH2Cl2
C17.5H22BrCl2F4N3O2Pt (Å)
103(OH)2
C24H18F8N4O2Pt [54]
(Å)
Pt-O12.029(9)2.015(6)2.028(7)2.061(3)2.017(3)
Pt-O22.003(8)1.999(6)2.016(6)2.018(3)2.008(3)
Pt-Cl2.349(3)2.359(3)2.345(3)2.3662 (11)n/a
Pt-N1(amide)2.031(9)2.026(9)2.037(9)2.047(3)2.033(3)
Pt-N2(amine)2.119(7)2.119(8)2.132(9)2.124(3)n/a
Pt-N3(py)2.078(7)2.087(8)2.066(9)2.061(3)2.083(3)
N1(amide)-C6F41.395(13)1.387(15)1.380(14)1.391(5)1.392(5)
C7(deen)-C8(deen)1.492(16)1.507(15)1.497(15)1.506(6)1.473(5)
N1(amide)-C7(deen)1.459(12)1.456(13)1.469(13)1.467 (5)1.470(5)
N2(amine)-C8(deen)1.508(14)1.497(13)1.504(13)1.510(6)n/a
N2(amine)-C9(Et)
N2(amine)-C11(Et)
1.510(14)
1.502(13)
1.510(13)
1.508(14)
1.514(14)
1.508(13)
1.497(5)
1.521(5)
n/a
n/a = not applicable.
Table 4. Inter- and intramolecular H-bonding interaction distances for 2·H2O(gold) and 3·0.5CH2Cl2.
Table 4. Inter- and intramolecular H-bonding interaction distances for 2·H2O(gold) and 3·0.5CH2Cl2.
2·H2O(gold)3·0.5CH2Cl2
InteractionsDistanceInteractionsDistance
F1⋯HO22.412(7)O2⋯ H(CH2CH3)2.3561(8)
F4⋯ HO12.438(7)F4⋯HO22.7065(7)
O1⋯ H(py)2.322(7)Cl⋯H(CH3)2.7529(7)
O2⋯ H(py)2.227(7)(CH2Cl2)Cl⋯H(CH2N(p-BrC6F4)3.0946(7)
O1⋯ H(CH2CH3)2.380(7)
Cl⋯H(CH3)2.738(3)Inter (CH2Cl2)Cl⋯H(CH2CH3)2.8282(4)
Inter O3H⋯O12.198(7)
Table 5. 1H and 19F NMR chemical shifts and assignments for 1H, 2·H2O(red), and 3·0.5CH2Cl2 in (CD3)2CO.
Table 5. 1H and 19F NMR chemical shifts and assignments for 1H, 2·H2O(red), and 3·0.5CH2Cl2 in (CD3)2CO.
1H NMR Chemical Shifts Assignment1H *
(ppm)
2·H2O(red)
(ppm)
3·0.5CH2Cl2
(ppm)
-NCH2CH31.56, td1.23, t1.26, t
-CH2NEt2-2.30, m2.30, m
=CHNEt23.75, d--
-NCHAHBCH32.30, m3.00, m3.00, m
-NCHAHBCH33.43, m3.13, m3.00, m
-CH2N(p-BrC6F4)-3.33, m3.47, m
=CHN(p-BrC6F4)6.07, m--
Pt-OH-4.03, m4.03, m
H 3, 5 (py)7.19, m7.33, t7.19, t
H 4 (py)7.74, tt7.86, t7.72, t
H 2,6 (py)8.42, d8.98, d8.98, d
19F NMR chemical shifts Assignment1H *
(ppm)
2·H2O(red)
(ppm)
3·0.5CH2Cl2
(ppm)
(p-BrC6F4) F 3,5−138.20, m−138.34, m−137.63, m
(p-BrC6F4) F 2,6−148.20, m−140.64, m−142.25, m
The data are extracted from complex NMR spectra of the compounds plus their reductive dehydration products. The full NMR data and integrations showing relative amounts are provided in the Experimental section. * For 2·H2O(gold), only 1H was observed. PtIV was not observed.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ojha, R.; Junk, P.C.; Bond, A.M.; Deacon, G.B. Oxidation of the Platinum(II) Anticancer Agent [Pt{(p-BrC6F4)NCH2CH2NEt2}Cl(py)] to Platinum(IV) Complexes by Hydrogen Peroxide. Molecules 2023, 28, 6402. https://doi.org/10.3390/molecules28176402

AMA Style

Ojha R, Junk PC, Bond AM, Deacon GB. Oxidation of the Platinum(II) Anticancer Agent [Pt{(p-BrC6F4)NCH2CH2NEt2}Cl(py)] to Platinum(IV) Complexes by Hydrogen Peroxide. Molecules. 2023; 28(17):6402. https://doi.org/10.3390/molecules28176402

Chicago/Turabian Style

Ojha, Ruchika, Peter C. Junk, Alan M. Bond, and Glen B. Deacon. 2023. "Oxidation of the Platinum(II) Anticancer Agent [Pt{(p-BrC6F4)NCH2CH2NEt2}Cl(py)] to Platinum(IV) Complexes by Hydrogen Peroxide" Molecules 28, no. 17: 6402. https://doi.org/10.3390/molecules28176402

APA Style

Ojha, R., Junk, P. C., Bond, A. M., & Deacon, G. B. (2023). Oxidation of the Platinum(II) Anticancer Agent [Pt{(p-BrC6F4)NCH2CH2NEt2}Cl(py)] to Platinum(IV) Complexes by Hydrogen Peroxide. Molecules, 28(17), 6402. https://doi.org/10.3390/molecules28176402

Article Metrics

Back to TopTop